However, the development of studies on the molecular characterization of AMLs has led to the identification of genetic abnormalities that can be specifically targeted by some drugs, such as inhibitors of isocitrate dehydrogenase (IDH), lysine demethylase 1 (LSD1), and Menin, capable of inducing AML differentiation. Here, IDH3A is linked to acute myeloid leukemia.